Responsiveness of classical kaposi's sarcoma to recombinant interferon alpha 2b treatment

M. Monti; M. Barbareschi; A. Angius; R. Caputo

doi:10.3109/09546639009086735

Responsiveness of classical kaposi's sarcoma to recombinant interferon alpha 2b treatment

M. Monti, M. Barbareschi, A. Angius, R. Caputo

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

Low doses of recombinant interferon alpha 2b were used to treat two patients with Kaposi's sarcoma not associated with AIDS. Clinical benefit was obtained after a few months in both cases. In one case dynamic telethermography demonstrated regression of the disease after 9 months of treatment. No serious side-effects were observed during interferon administration. We conclude that recombinant interferon alpha 2b could be considered a treatment of choice for Kaposi's sarcoma not associated with AIDS.

Original language	English
Pages (from-to)	209-210
Number of pages	2
Journal	Journal of Dermatological Treatment
Volume	1
Issue number	4
DOIs	https://doi.org/10.3109/09546639009086735
Publication status	Published - 1990

ASJC Scopus subject areas

Dermatology

Access to Document

10.3109/09546639009086735

Fingerprint Dive into the research topics of 'Responsiveness of classical kaposi's sarcoma to recombinant interferon alpha 2b treatment'. Together they form a unique fingerprint.

Cite this

@article{1c545f13965347a4a3e3d9500f169751,

title = "Responsiveness of classical kaposi's sarcoma to recombinant interferon alpha 2b treatment",

abstract = "Low doses of recombinant interferon alpha 2b were used to treat two patients with Kaposi's sarcoma not associated with AIDS. Clinical benefit was obtained after a few months in both cases. In one case dynamic telethermography demonstrated regression of the disease after 9 months of treatment. No serious side-effects were observed during interferon administration. We conclude that recombinant interferon alpha 2b could be considered a treatment of choice for Kaposi's sarcoma not associated with AIDS.",

author = "M. Monti and M. Barbareschi and A. Angius and R. Caputo",

year = "1990",

doi = "10.3109/09546639009086735",

language = "English",

volume = "1",

pages = "209--210",

journal = "Journal of Dermatological Treatment",

issn = "0954-6634",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Responsiveness of classical kaposi's sarcoma to recombinant interferon alpha 2b treatment

AU - Monti, M.

AU - Barbareschi, M.

AU - Angius, A.

AU - Caputo, R.

PY - 1990

Y1 - 1990

N2 - Low doses of recombinant interferon alpha 2b were used to treat two patients with Kaposi's sarcoma not associated with AIDS. Clinical benefit was obtained after a few months in both cases. In one case dynamic telethermography demonstrated regression of the disease after 9 months of treatment. No serious side-effects were observed during interferon administration. We conclude that recombinant interferon alpha 2b could be considered a treatment of choice for Kaposi's sarcoma not associated with AIDS.

AB - Low doses of recombinant interferon alpha 2b were used to treat two patients with Kaposi's sarcoma not associated with AIDS. Clinical benefit was obtained after a few months in both cases. In one case dynamic telethermography demonstrated regression of the disease after 9 months of treatment. No serious side-effects were observed during interferon administration. We conclude that recombinant interferon alpha 2b could be considered a treatment of choice for Kaposi's sarcoma not associated with AIDS.

UR - http://www.scopus.com/inward/record.url?scp=0025037220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025037220&partnerID=8YFLogxK

U2 - 10.3109/09546639009086735

DO - 10.3109/09546639009086735

M3 - Article

AN - SCOPUS:0025037220

VL - 1

SP - 209

EP - 210

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 4

ER -